English | Deutsch | Français | Italiano | Español

Coronavirus SARS-CoV-2

The spread of SARS-CoV-2 has become a serious challenge for public health, economy and social life in Europe and other regions of the world. To flatten the curve of new infections, not only social distancing and restrictions in public life but also fast and reliable testing plays an essential role.

As a leading provider of medical diagnostic services, SYNLAB is fulfilling its special responsibility in this challenging situation for the healthcare systems and the people in the various countries we are operating in. SYNLAB proactively partners with the competent authorities in order to support them with our medical expertise.

We are leveraging our diagnostics capabilities to support countries in the fight against the coronavirus SARS-CoV-2.

Recent medical releases

30.04.2020

A safe return

Minimizing risk of new Sars-CoV-2 infections before returning to the workplace

Category: Recent medical releases
30.04.2020

200,000 serological antibody tests per week

SYNLAB ramps up capacity for CE-IVD certified tests of the latest generation 

Category: Recent medical releases
21.04.2020

The right test at the right time

Recommendations for SARS-CoV-2 testing in different clinical situations 

Category: SARS-CoV-2, Corporate News, Corporation, Recent medical releases

Below you can find examples of SYNLAB's engagement across Europe and beyond highlighting the Group's contribution in the fight against the virus.

14.05.2020

Italy: SYNLAB joins the epidemiological study "Mustang Occupation"

SYNLAB has been invited to join the "Mustang Occupation" epidemiological study, the first serological investigation on a voluntary basis launched by IRCSS MultiMedica in collaboration with the University of Milan-Bicocca, which …

Category: SARS-CoV-2
09.05.2020

France: Cannes City Hall is conducting its Covid-19 offensive screening campaign

Cannes has launched a first phase of RT-PCR offensive screening for fragile and vulnerable people, municipal, inter-municipal and CCAS staff in direct contact with the public: already 2,900 people tested.

Category: SARS-CoV-2
08.05.2020

Italy: Serological tests available in authorised laboratories, including SYNLAB

From Tuesday 12 May onward, every citizen with a prescription will be able to undergo the examination.

Category: SARS-CoV-2
23.04.2020

Spanish football league (LaLiga Santander) chooses SYNLAB as partner to test all the teams

LaLiga players will receive the COVID-19 test from April 28

Category: SARS-CoV-2

We are leveraging our diagnostics capabilities to support countries in the fight against the coronavirus SARS-CoV-2. SYNLAB has continuously expanded its testing capacity for SARS-CoV-2 and continues to expand it in order to best meet the growing demand. We are working very closely with our suppliers to ensure the continuity of our stocks. At the same time, we are constantly optimising the use of resources in our laboratory network in order to guarantee a maximum number of tests.

However, test capacities are not unlimited. It is therefore important that everybody adheres to the guidelines of public health authorities (such as WHO or Robert-Koch-Institute) as well as the official orders and guidelines of national governments and the European Union. On top of increasing our current testing capacity we are also engaged in developing the next generation of tests which would significantly improve the number of tests that can be done or provide quicker results.

We have 1,300 doctors and scientists fully engaged to ensure continuity of service, together with our patient facing employees, our laboratory technicians, logistics teams and our support functions. We are in a position to maintain our full offering of tests.  We have contingency and business continuity plans in place and are not only closely monitoring the dissemination of the virus but especially potential restrictions imposed by authorities. SYNLAB will take appropriate measures if necessary and depending on the individual situation in the countries we are operating in.